TABLE 1.
Summary of studies
| Study feature | Number of studies | Proportion of studies (%) |
|---|---|---|
| Country | ||
| North America | 26 | 48.15 |
| Europe | 16 | 29.63 |
| Asia | 9 | 16.67 |
| Mixed continents | 2 | 3.70 |
| Australasia | 1 | 1.85 |
| Selection of patients | ||
| Unselected | 34 | 62.96 |
| Selected | 20 | 37.04 |
| Histology | 14 | 25.93 |
| EC | 4 | 7.40 |
| CCC | 4 | 7.40 |
| EC + CCC | 3 | 5.56 |
| Non‐HGS | 1 | 1.85 |
| Non‐CCC | 1 | 1.85 |
| Non‐serous + non‐mucinous | 1 | 1.85 |
| Age | 4 | 7.40 |
| Stage | 1 | 1.85 |
| Gene | 1 | 1.85 |
| Primary tests for MMRd conducted on unselected patients | ||
| IHC | 12 | 35.29 |
| MSI | 10 | 29.41 |
| GL | 7 | 20.59 |
| IHC + MSI | 2 | 5.88 |
| GL + MSI | 1 | 2.94 |
| GL + somatic | 1 | 2.94 |
| IHC + MSI + somatic | 1 | 2.94 |